Interventionelle Kardiologie Spandau, Berlin, Germany; Universitätsmedizin Berlin, Charite Campus Mitte, Berlin, Germany.
HyTest Ltd., Intelligate 6th floor, Joukahaisenkatu 6, 20520 Turku, Finland.
Clin Biochem. 2014 Feb;47(3):177-83. doi: 10.1016/j.clinbiochem.2013.10.027. Epub 2013 Nov 5.
We have previously reported that increases in total pregnancy-associated plasma protein-A (PAPP-A) which are thought to be indicative of vulnerable plaques and thus poor outcomes predict outcomes in patients with stable coronary artery disease. We hypothesized that the determination of CT- and NT-fragments of insulin-like growth factor binding protein 4 (CT- and NT-IGFBP4) which should be indicative of free PAPP-A would result in better performance.
In 229 stable cardiovascular patients with indication for heart catheterization after performance of a stress test and an echocardiogram, CT- and NT-IGFBP4 were measured. Their values were investigated in relation to clinical characteristics, findings of noninvasive investigations, laboratory data and coronary angiography as well as to outcomes after a follow-up of 1094±307days.
CT-IGFBP4 values were independently predicted by patients with B-type (p=0.0069) or complex coronary lesions (p=0.0445). B-type and vulnerable coronary lesions were independently predicted by levels of CT-IGFBP4≥a cutoff of 31.55ng/mL derived from ROC analysis (p=0.0090 and 0.0480). NT-IGFBP4 was not predictive of coronary characteristics. Both IGFBP4 fragments were strongly dependent on age and renal function and were not predictive of outcomes.
Despite the relation of CT-IGFBP4 to a more severe coronary artery disease, CT- and NT-IGFBP4, in contrast to our report based on total PAPP-A, failed to predict any long-term outcomes in patients with stable cardiovascular disease. Further knowledge about the interaction of the PAPP-A-insulin-like growth factor system is needed to explain values of IGFBP4 fragments in these patients.
我们之前曾报道过,总妊娠相关血浆蛋白-A(PAPP-A)的增加,被认为是易损斑块的指标,因此预测稳定型冠状动脉疾病患者的预后较差。我们假设,胰岛素样生长因子结合蛋白 4(CT-和 NT-IGFBP4)的 CT-和 NT-片段的测定,应该可以指示游离的 PAPP-A,从而可以获得更好的结果。
在 229 例因进行压力测试和超声心动图检查而需要进行心脏导管检查的稳定型心血管患者中,测量了 CT-和 NT-IGFBP4。研究了它们的值与临床特征、无创检查结果、实验室数据和冠状动脉造影以及在 1094±307 天后的随访结果之间的关系。
CT-IGFBP4 值可独立预测 B 型(p=0.0069)或复杂的冠状动脉病变(p=0.0445)患者。B 型和易损性冠状动脉病变可独立预测 CT-IGFBP4 水平≥31.55ng/mL 的截断值(p=0.0090 和 0.0480)。NT-IGFBP4 对冠状动脉特征无预测作用。两种 IGFBP4 片段均强烈依赖于年龄和肾功能,不能预测预后。
尽管 CT-IGFBP4 与更严重的冠状动脉疾病有关,但与我们基于总 PAPP-A 的报告相反,CT-和 NT-IGFBP4 未能预测稳定型心血管疾病患者的任何长期预后。需要进一步了解 PAPP-A-胰岛素样生长因子系统的相互作用,以解释这些患者 IGFBP4 片段的值。